Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Abstract Background Despite a high asthma burden in Kenya, insights into asthma management practices, including prescription of short-acting β2-agonists (SABAs), are lacking. Therefore, this study describes patient demographics, disease characteristics, and asthma treatment patterns in the Kenyan co...

Full description

Bibliographic Details
Main Authors: Jeremiah Chakaya, Jared Mecha, Maarten Beekman
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Primary Care
Subjects:
Asthma management
Over-the-counter
Prescription
SABA
Short-acting β2-agonist
Online Access:https://doi.org/10.1186/s12875-023-02030-8

Internet

https://doi.org/10.1186/s12875-023-02030-8

Similar Items